Clinical and biological relationship between chronic lymphocytic thyroiditis and papillary thyroid carcinoma

Oncology Research

Volumn 17, Issue 10, 2009, Pages 495-503

  Antonaci, Alfredo ^a   Consorti, Fabrizio ^a   Mardente, Stefania ^a   Giovannone, Gloria ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Apoptosis; Chronic lymphocytic thyroiditis; Oncogenes; Papillary thyroid carcinoma

Indexed keywords

B RAF KINASE; COLONY STIMULATING FACTOR 1; CYCLOOXYGENASE 2; CYTOKERATIN 19; FIBRONECTIN; GALECTIN 3; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1ALPHA; MITOCHONDRIAL DNA; OSTEOPONTIN; PROTEIN PATCHED; PROTEIN RET; THROMBOXANE SYNTHASE;

APOPTOSIS; AUTOIMMUNITY; CANCER CELL; FOLLICULAR CARCINOMA; GENE MUTATION; HASHIMOTO DISEASE; HETEROZYGOSITY LOSS; HUMAN; HYPOTHYROIDISM; INCIDENCE; LARGE CELL LYMPHOMA; LYMPHOCYTIC INFILTRATION; LYMPHOCYTIC THYROIDITIS; LYMPHOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THYROID PAPILLARY CARCINOMA; TUMOR IMMUNITY; PAPILLARY CARCINOMA; PATHOLOGY; THYROID TUMOR;

CARCINOMA, PAPILLARY; HASHIMOTO DISEASE; HUMANS; THYROID NEOPLASMS;

EID: 70349337728     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504009789735431     Document Type: Review

References (82)

1. Dailey, M. E.; Lindsay, S.; Skahen, R. Relation of thyroid neoplasms to Hashimoto's disease of the thyroid gland. AMA Arch. Surg. 70:291-297; 1955.
2. Ott, R. A.; McCall, A. R.; McHenry, C.; et al. The incidence of thyroid carcinoma in Hashimoto's thyroiditis. Am. Surg. 53:442-445; 1987.
3. Okayasu, I.; Fujiwara, M.; Hara, Y.; Tanaka, Y.; Rose, N. R. Association of chronic lymphocytic thyroiditis and thyroid papillary carcinoma. A study of surgical cases among Japanese, and white and African Americans. Cancer 76(11):2312-2318; 1995.
4. Singh, B.; Shaha, A. R.; Trivedi, H.; Carew, J. F.; Poluri, A.; Shah, J. P. Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: Impact on presentation, management, and outcome. Surgery 26(6):1070-1076; 1999.
5. Braverman, L. E. Iodine and the thyroid: 33 years of study. Thyroid 4:351-356; 1994.
6. Bindra, A.; Braunstein, G. D. Thyroiditis. Am. Fam. Physician 73(10):1769-1776; 2006.
7. Feldt-Rasmussen, U. Iodine and cancer. Thyroid 11(5): 483-486; 2001.
8. Eisenberg, B. L.; Hensley, S. Thyroid cancer with coexistent Hashimoto's thyroiditis. Clinical assessment and management. Arch. Surg. 124:1045-1047; 1989.
9. Tamimi, D. M. The association between chronic lymphocytic thyroiditis and thyroid tumors. Int. J. Surg. Pathol. 10:141-146; 2002.
10. Kebebew, E.; Treseler, P. A.; Ituarte, P. H.; Clark, O. H. Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. World J. Surg. 25:632-637; 2001.
11. Schaffler, A.; Palitzsch, K. D.; Seiffarth, C.; Hohne, H. M.; Riedhammer, F. J.; Hofstadter, F.; Scholmerich, J.; Ruschoff, J. Coexistent thyroiditis is associated with lower tumour stage in thyroid carcinoma. Eur. J. Clin. Invest. 28:838-844; 1998.
12. Ott, R. A.; Calandra, D. B.; McCall, A.; Shah, K. H.; Lawrence, A. M.; Paloyan, E. The incidence of thyroid carcinoma in patients with Hashimoto's thyroiditis and solitary cold nodules. Surgery 98:1202-1206; 1985.
13. Souza, S. L.; Montalli Da Assumpcao, L. V.; Ward, L. S. Impact of previous thyroid autoimmune diseases on prognosis of patients with well-differentiated thyroid cancer. Thyroid 13(5):491-495; 2003.
14. Pacini, F.; Vorontsova, T.; Molinaro, E.; Kuchinskaya, E.; Agate, L.; Shavrova, E.; Astachova, L.; Chiovato, L.; Pinchera, A. Prevalence of thyroid autoantibodies in children and adolescents from Belarus exposed to the Chemobyl radioactive fallout. Lancet 352:763-766; 1998.
15. Kashima, K.; Yokoyama, S.; Noguchi, S.; Murakami, N.; Yamashita, H.; Watanabe, S.; Uchino, S.; Toda, M.; Sasaki, A.; Daa, T.; Nakayama, I. Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma. Thyroid 8(3):197-202; 1998.
16. Loh, K. C.; Greenspan, F. S.; Doug, F.; Miller, T. R.; Yeo, P. P. Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 84(2):458-463; 1999.
17. Di Pasquale, M.; Rothstein, J.; Palazzo, J. P. Pathologic features of Hashimoto's -associated papillary thyroid carcinoma. Hum. Pathol. 32(1):24-30; 2001.
18. Prasad, M. L.; Huang, Y.; Pellegata, N. S.; De La Chapelle, A.; Kloos, R. T. Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC. Histopathology 45: 39-46; 2004.
19. Arif, S.; Blanes, A.; Diaz-Cano, S. J. Hashimoto's thyroiditis shares features with early papillary thyroid carcinoma. Histopathology 41:357-362; 2002.
20. Vanni, R.; Marras-Virdis, S.; Gerosa, C.; Lai, M. L.; Tallini, G. Cytogenetics of thyroid nodules in Hashimoto thyroiditis. Cancer Genet. Cytogenet. 120:87-88; 2000.
21. Hunt, J. L.; Baloch, Z. W.; Barnes, L.; Swalsky, P. A.; Trusky, C. L.; Sesatomi, E.; Finkelstein, S.; LiVolsi, V. A. Loss of heterozygosity mutations of tumor suppressor genes in cytologically atypical areas in chronic lymphocytic thyroiditis. Endocr. Pathol. 13:321-330; 2002.
22. Gasbarri, A.; Sciacchitano, S.; Marasco, A.; Papotti, M.; Di Napoli, A.; Marzullo, A.; Yushkov, P.; Ruco, L.; Bartolazzi, A. Detection and molecular characterisation of thyroid cancer precursor lesions in a specific subset of Hashimoto's thyroiditis. Br. J. Cancer 91:1096-1104; 2004.
23. Santoro, M.; Sabino, N.; Ishizaka, Y.; Ushijima, T.; Carlomagno, F.; Cerrato, A.; Grieco, M.; Battaglia, C.; Martelli, M. L.; Paulin, C. Involvement of RET oncogene in human tumours: Specificity of RET activation to thyroid tumours. Br. J. Cancer 68:460-464; 1993.
24. Santoro, M.; Melillo, R. M.; Carlomagno, F.; Fusco, A.; Vecchio, G. Molecular mechanisms of RET activation in human cancer. Ann. NY Acad. Sci. 963:116-121; 2002.
25. Bounacer, A.; Wicker, R.; Caillou, B.; Cailleux, A. F.; Sarasin, A.; Schlumberger, M.; Suárez, H. G. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene 15:1263-1273; 1997.
26. Bongarzone, I.; Pierotti, M.; Monzini, N.; Mondellini, P.; Manenti, G.; Donghi, S. R.; Pilotti, S.; Grieco, M.; Santoro, M.; Fusco, A., Vecchio, G.; Della-Porta, G. High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene 4:1457-1462; 1989.
27. Rhoden, K. J.; Johnson, C.; Brandao, G.; Howe, J. G.; Smith, B. R.; Tallini, G. Real-time quantitative RT-PCR identifies distinct c-RET, RET/ PTC1 and RET/PTC3 expression patterns in papillary thyroid carcinoma. Lab. Invest. 84:1557-1570; 2004.
28. Unger, K.; Zitzelsberger, H.; Salvatore, G.; Santoro, M.; Bogdanova, T.; Braselmann, H.; Kastner, P.; Zurnadzhy, L.; Tronko, N.; Hutzler, P.; Thomas, G. Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas. J. Clin. Endocrinol. Metab. 89:4272-4279; 2004.
29. Sheils, O. M.; O'Eary, J. J.; Uhlmann, V.; Lattich, K.; Sweeney, E. C. Ret/PTC-1 activation in Hashimoto thyroiditis. Int. J. Surg. Pathol. 8:185-189; 2000.
30. Wirtschafter, A.; Schmidt, R.; Rosen, D.; Kundu, N.; Santoro, M.; Fusco, A.; Multhaupt, H.; Atkins, J.; Rosen, M.; Keane, W.; Rothstein, J. L. Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. Laryngoscope 107:95-100; 1997.
31. Mechler, C.; Bounacer, A.; Suarez, H.; Saint Frison, M.; Magois, C.; Aillet, G.; Gaulier, A. Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements. Br. J. Cancer 85(12):1831-1837; 2001.
32. Nikiforova, M. N.; Caudill, C. M.; Biddinger, P.; Nikiforov, Y. E. Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas. Int. J. Surg. Pathol. 10(1):15-22; 2002.
33. Rhoden, K. J.; Unger, K.; Salvatore, G.; Yilmaz, Y.; Vovk, V.; Chiappetta, G.; Qumsiyeh, M. B.; Rothstein, J. L.; Fusco, A.; Santoro, M.; Zitzelsberger, H.; Tallini, G, RET/Papillary thyroid cancer rearrangement in non-neoplastic thyrocytes: Follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. J. Clin. Endocrinol. Metab. 91: 2414-2423; 2006.
34. Hunt, J. L. Molecular testing in solid tumors: An overview. Arch. Pathol. Lab. Med. 132(2):164-167; 2008.
35. Nikiforova, M. N.; Nikiforov, Y. E. Molecular genetics of thyroid cancer: Implications for diagnosis, treatment and prognosis. Expert Rev. Mol. Diagn. 8(1):83-95; 2008.
36. Xing, M. BRAF mutation in thyroid cancer. Endocrine Related Cancer 12:245-262; 2005.
37. Kyung-Hee, K.; Kwang-Sun, S.; Dong-Wook, K.; Dae-Young, K. Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis. Pathol. Int. 55:540-545; 2005.
38. Kang, D. Y.; Kim, K. H.; Kim, J. M.; Kim, S. H.; Kim, J. Y.; Baik, H. W.; Kim, Y. S. High prevalence of RET, RAS, and ERK expression in Hashimoto's thyroiditis and in papillary thyroid carcinoma in the Korean population. Thyroid 17(11):1031-1038; 2007.
39. Sargent, R.; LiVolsi, V.; Murphy, J.; Mantha, G.; Hunt, J. L. BRAF mutation is unusual in chronic lymphocytic thyroiditis-associated papillary thyroid carcinomas and absent in non-neoplastic nuclear atypia of thyroiditis. Endocr. Pathol. 17(3):235-241; 2006.
40. Caturegli, P.; Kimura, H.; Rocchi, R.; Rose, N. R. Autoimmune thyroid diseases. Curr. Opin. Rheumatol. 19:44-48; 2007.
41. Fountoulakis, S.; Tsatsoulis, A. On the pathogenesis of autoinumme thyroid disease: A unifying hypothesis. Clin. Endocrinol. 60:397-409; 2004.
42. Boyd, C. M.; Baker, J. R. The immunology of thyroid cancer. Endocrinol. Metab. Clin. North Am. 25(1):159-179; 1996.
43. Santoro, M.; Melillo, R. M.; Fusco, A. RET/PTC activation in papillary thyroid carcinoma. Eur. J. Endocrinol. 155(5):645-653; 2006.
44. Borrello, M. G.; Alberti, L.; Fischer, A.; Degl'innocenti, D.; Ferrario, C.; Gariboldi, M.; Marchesi, F.; Allavena, P.; Greco, A.; Collini, P.; Pilotti, S.; Cassinelli, G.; Bressan, P.; Fugazzola, L.; Mantovani, A.; Pierotti, M. A. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc. Natl. Acad. Sci. USA 102:14825-14830; 2005.
45. Russell, J. P.; Shinohara, S.; Melillo, R. M.; Castellone, M. D.; Santoro, M.; Rothstein, J. L. Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors. Oncogene 22:4569-4577; 2003.
46. Puxeddu, E.; Knauf, J. A.; Sartor, M. A.; Mitsutake, N.; Smith, E. P.; Medvedovic, M.; Tomlinson, C. R.; Moretti, S.; Fagin, J. A. RET/ PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response. Endocrine Related Cancer 12:319-334; 2005.
47. Castellone, M. D.; Guarino, V.; De Falco, V.; Carlomagno, F.; Basolo, F.; Faviana, P.; Kruhoffer, M.; Orntoft, T.; Russell, J. P.; Rothstein, J. L.; Fusco, A.; Santoro, M.; Melillo, R. M. Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas. Oncogenc 23:5958-5967; 2004.
48. Melillo, R. M.; Castellone, M. D.; Guarino, V.; De Falco, V.; Cirafici, A. M.; Salvatore, G.; Caiazzo, F.; Basolo, F.; Giannini, R.; Kruhoffer, M.; Orntoft, T.; Fusco, A.; Santoro, M. The RET/PTC-RAS-BRAF. linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J. Clin. Invest. 115(4):1068-1081; 2005.
49. Puxeddu, E.; Mitsutake, N.; Knauf, J. A.; Moretti, S.; Kim, H. W.; Seta, K. A.; Brockman, D.; Myatt, L.; Millhorn, D. E.; Fagin, J. A. Microsomal prostaglandin E2 synthase-1 is induced by conditional expression of RET/ PTC in thyroid PCCL3 cells through the activation of the MEK-ERK pathway. J. Biol. Chem. 278:52131-52138; 2003.
50. Castellone, M. D.; Celetti, A.; Guarino, V.; Cirafici, A. M.; Basolo, F.; Giannini, R.; Medico, E.; Kruhoffer, M.; Orntoft, T. F.; Curcio, F.; Fusco, A.; Melillo, R. M.; Santoro, M. Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells. Oncogene 23(12): 2188-2196; 2004.
51. Reines, B. P. Hypothesis. Bystanders or bad seeds? Many autoimmune-target cells be transforming to cancer and signalling "danger" to the immune system. Autoimmunity 33(2):121-134; 2001.
52. Matsubayashi, S.; Kawai, K.; Matsumoto, Y.; Mukuta, T.; Morita, T.; Hirai, K.; Matsuzuka, F.; Kakudoh, K. I.; Kuma, K.; Tamai, H. The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland. J. Clin. Endocrinol. Metab. 80:3421-3424; 1995.
53. Fiumara, A.; Belfiore, A.; Russo, G.; Salomone, E.; Santonocito, G. M.; Ippolito, O.; Vigneri, R.; Gangemi, P. In situ evidence of neoplastic cell phagocytosis by macrophages in papillary thyroid cancer. J. Clin. Endocrinol. Metab. 82(5):1615-1620; 1997.
54. Ozaki, O.; Ito, K.; Mimura, T.; Sugino, K.; Hosoda, Y. Papillary carcinoma of the thyroid: tall-cell variant with extensive lymphocyte infiltration. Am. J. Sing. Pathol. 20(6):695-698; 1996.
55. Scouten, W.; Francis, G. L. Thyroid cancer and the immune system: A model for effective immune surveillance. Expert Rev. Endocrinol. Metab. 1(3):353; 2006.
56. Costello, A.; Rey-Hipolito, C.; Patel, A.; Oakley, K.; Vasco, V.; Calabria, C.; Tuttle, R. M.; Francis, G. L. Thyroid cancers express CD-40 and CD-40 ligand: Cancers that express CD-40 ligand may have a greater risk of recurrence in young patients. Thyroid 15(2):105-113; 2005.
57. Prescott, S. M.; Fitzpatrick, F. A. Cyclooxygenase-2 and carcinogenesis. Biochim. Biophys. Acta 1470:69-78; 2000.
58. Berg, J.; Stöcher, M.; Bogner, S.; Wölfl, S.; Pichler, R.; Stekel, H. Inducible cyclooxygenase-2 gene expression in the human thyroid epithelial cell line Nthy-ori3-1. Inflanim. Res. 49:139-143; 2000.
59. Nose, F.; Ichikawa, T.; Fujiwara, M.; Okayasu, I. Upregulation of cyclooxygenase-2 expression in lymphocytic thyroiditis and thyroid tumors: significant correlation with inducible nitric oxide synthase. Am. J. Clin. Pathol. 117(4):546-551; 2002.
60. Cornetta, A. J.; Russell, J. P.; Cunnane, M.; Keane, W. M.; Rothstein, J. L. Cyclooxygenase-2 expression in human thyroid carcinoma and Hashimoto's thyroiditis. Laryngoscope 112(2):238-242; 2002.
61. Ito, Y.; Yoshida, H.; Nakano, K.; Takamura, Y.; Miya, A.; Kobayashi, K.; Yokozawa, T.; Matsuzuka, F.; Matsuura, N.; Kuma, K.; Miyauchi, A. Cyclooxygenase-2 expression in thyroid neoplasms. Histopathology 42(5):492-497; 2003.
62. Casey, M. B.; Zhang, S.; Jin, L.; Kajita, S.; Lloyd, R. V. Expression of cyclooxygenase-2 and thromboxane synthase in non-neoplastic and neoplastic thyroid lesions. Endocr. Pathol. 15(2):107-116; 2004.
63. Prasad, M. L.; Huang, Y.; Pellegata, N. S.; De La Chapelle, A.; Kloos, R. T. Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC. Histopathology 45: 39-46; 2004.
64. Gupta, S.; Joshi, K.; Wig, J. D,; Arora, S. K. Intratumoral FOXP3 expression in infiltrating breast carcinoma: Its association with clinicopathologic parameters and angiogenesis. Acta. Oncol. 46(6):792-797; 2007.
65. Ban, Y.; Tozaki, T.; Tobe, T.; Ban, Y.; Jacobson, E. M.; Concepcion, E. S.; Tomer, Y. The regulatory T cell gene FOXP3 and genetic susceptibility to thyroid autoimmunity: An association analysis in Caucasian and Japanese cohorts. Autoinimunity 28(4):201-207; 2007.
66. Okayasu, I.; Saegusa, M.; Fujiwara, M.; Hara, Y.; Rose, N. R. Enhanced cellular proliferative activity and cell death in chronic thyroiditis and thyroid papillary carcinoma. J. Cancer Res. Clin. Oncol. 121:746-752; 1995.
67. Stokes, T. A.; Rymaszewski, M.; Arscott, P. L.; Wang, S. E.; Bretz, J. D.; Bartron, J.; Baker, J. R.; Fiedler, P.; Schaetzlein, C. E.; Eibel, H.; Papoff, G.; Stassi, G.; De Maria, R.; Giordano, C.; Galluzzo, A.; Bagnasco, M.; Ruberti, G.; Testi, R. Constitutive expression of FasL in thyrocytes. Science 279:2015; 1998.
68. Giordano, C.; Stassi, G.; De Maria, R.; Todaro, M.; Richiusa, P.; Papoff, G.; Ruberti, G.; Bagnasco, M.; Testi, R.; Galluzzo, A. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 275: 960-963; 1997.
69. Hammond, L. J.; Lowdell, M. W.; Cerrano, P. G.; Goode, A. W.; Bottazzo, G. F.; Mirakian, R. Analysis of apoptosis in relation to tissue destruction associated. with Hashimoto's autoimmune thyroiditis. J. Pathol. 182:138-144; 1997.
70. Arscott, P. L. Fas (CD 95) expression is up-regulated on papillary thyroid carcinoma. Clin. Endocrinol. Metab. 84(11):4246-4252; 1999.
71. Arscott, P. L.; Knapp, J.; Rymaszewski, M. Fas (APO-1, CD95)-mediated apoptosis in thyroid cells is regulated by a labile protein inhibitor. Endocrinology 138:5019-5027; 1997.
72. Stassi, G.; Todaro, M.; Zerilli, M.; Ricci-Vitiani, L.; Di Liberto, D.; Patti, M.; Florena, A.; Di Gaudio, F.; Di Gesu, G.; De Maria, R. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res. 63(20):6784-6790; 2003.
73. Hiromatsu, Y.; Hiromatsu, Y.; Hoshino, T.; Yagita, H.; Koga, M.; Sakisaka, S.; Honda, J.; Yang, D.; Kayagaki, N.; Okumura, K.; Nonaka, K. Functional Fas ligand expression in thyrocytes from patients with Graves' disease. J. Clin. Endocrinol. Metab. 84(8):2896-2902; 1999.
74. Mardente, S.; Lenti, L.; Lococo, E.; Consorti, F.; Della Rocca, C.; Romeo, S.; Misasi, R.; Antonaci, A. Phenotypic and functional characterization of lymphocytes in autoimmune thyroiditis and in papillary carcinoma. Anticancer Res. 25(3c):2483-2488; 2005.
75. Schuetz, M.; Duan, H.; Wahl, K.; Pirich, C.; Antoni, A.; Kommata, S.; Kletter, K.; Dudczak, R.; Karanikas, G.; Willheim, M. T lymphocyte cytokine production patterns in hashimoto patients with elevated calcitonin levels and their relationship to tumor initiation. Anticancer Res. 26(6B):4591-4596; 2006.
76. Sobrinho-Simões, M.; Máximo, V.; Castro, I. V.; Fonseca, E.; Soares, P.; Garcia-Rostan, G.; Oliveira, M. C. Hürthle (oncocytic) cell tumors of thyroid: Etiopathogenesis, diagnosis and clinical significance. Int. J. Surg. Pathol. 13(1): 29-35; 2005.
77. Unger, P. Expression of p63 in papillary thyroid carcinoma and in Hashimoto thyroiditis: A pathobiological link? Hum. Pathol. 34(8):764-769; 2003.
78. Burstein, D. E.; Nagi, C.; Wang, B.; Unger, P. Immunohistochemical detection of p53 homolog p63 in solid cell nests, papillary thyroid carcinoma, and Hashimoto's thyroiditis: A stem cell hypothesis of papillary carcinoma. Oncogenesis Hum. Pathol. 35(4):465-470; 2004.
79. Matsumoto, F.; Fujii, H.; Abe, M.; Kajino, K.; Kobayashi, T.; Matsumoto, T.; Ikeda, K.; Hino, O. A novel tumor marker, Niban, is expressed in subsets of thyroid tumors and Hashimoto's thyroiditis. Hum. Pathol. 37:1592-1600; 2006.
80. Jaffe, E. S.; Harris, N. L.; Stein, H.; Vardiman, J. M. WHO classification of tumors-pathology and genetica of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
81. Isaacson, P. G.; Du, M. Q. MALT lymphoma: from morphology to molecules. Nat. Rev. Cancer 4(8):644-653; 2004.
82. Tamimi, D. M. The association between chronic lymphocytic thyroiditis and thyroid tumors. Int. J. Surg. Pathol. 10(2):141-146; 2002.